Anemia, Sickle Cell clinical trials

The registry lists 1,134 studies for Anemia, Sickle Cell across more than 10 countries. 238 are recruiting or about to start. 888 of them are mainly about Anemia, Sickle Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 4 narrower conditions too, such as Vaso-Occlusive Crises: 1,176 studies, 243 open.

ClinicalTrials.gov finds 1,210 studies for Anemia, Sickle Cell. How that becomes 1,132 here

This page counts the studies the registry files under Anemia, Sickle Cell, and those it files under no condition that list Anemia, Sickle Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

1,210Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−42Filed under a narrower condition, counted on its own pageSickle Cell Trait 15 · Vaso-Occlusive Crises 15 · Hemoglobin SC Disease 6 · Acute Chest Syndrome 5
−5List Anemia, Sickle Cell as a condition, but the registry did not file them under itMost often written as “Sickle Cell Anemia in Children” (3) and “Healthy Volunteers Sickle Cell Disease, Thalassemia” (2). The registry filed them under other conditions only, most often Thalassemia (2) and Vitamin D Deficiency (1).
−31Match it another way27 name it in the title and 4 by a synonym or other text the search reads.
1,132The count on this page12 of them list Anemia, Sickle Cell in their own words; the registry filed them under no condition.

Get an email when these change. Save the Anemia, Sickle Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 604
Recruiting: 177
Terminated: 125
Active, not recruiting: 62
Status unknown: 55
Not yet recruiting: 48

Phase

Phase 2: 297
Phase 1: 184
Phase 3: 109
Phase 4: 38
Early Phase 1: 15

Where

United States: 733
France: 132
United Kingdom: 76
Canada: 55
Italy: 43
Nigeria: 37

Who runs them

National Heart, Lung, and Blood Institute (NHLBI) (61) · Assistance Publique - Hôpitaux de Paris (48) · St. Jude Children's Research Hospital (45) · Children's Hospital Medical Center, Cincinnati (30) · Emory University (29) · Pfizer (27) · Duke University (25) · Novartis Pharmaceuticals (22)

What is being tested here

Drugs under test in Anemia, Sickle Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Hydroxyurea	8	11	58
Alemtuzumab	6	2	22
Sirolimus	5	0	15
Fludarabine	4	2	22
Cyclophosphamide	3	1	19
Crizanlizumab	3	2	10
Etavopivat	3	2	8
Thiotepa	3	0	7
BRL-101	3	0	3
Ketamine	2	2	9

Drug classes tested here Antimetabolites 10 open · Alkylating agents 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Opioids 2 open · Calcineurin inhibitors 2 open

Coming up

24phase 3 studies under way

86studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jan 2027Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease · Phase 3 · Sanofi
Mar 2027RElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease · Phase 3 · King's College Hospital NHS Trust
Apr 2027Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease · Phase 3 · Assistance Publique - Hôpitaux de Paris
May 2027A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease · Phase 3 · bluebird bio
Jun 2027A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis · Phase 3 · Asklepion Pharmaceuticals, LLC
Jun 2027Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) · Phase 3 · Vertex Pharmaceuticals Incorporated
Jun 2027Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease · Phase 3 · Vertex Pharmaceuticals Incorporated
Jul 2027The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease · Phase 3 · Sanofi
Aug 2027A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease · Phase 3 · Novo Nordisk A/S
Nov 2026Cooperative Assessment of Late Effects for SCD Curative Therapies · Vanderbilt University Medical Center

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger. 127 (72%) take children under 18. 6 (3%) are for women only and 0 (0%) for men only; 29 (16%) take healthy volunteers.

Recruiting studies that take each age, of 177
Age	Women	Men
10	79 (45%)	78 (44%)
18	153 (86%)	148 (84%)
30	121 (68%)	117 (66%)
40	109 (62%)	105 (59%)
50	104 (59%)	100 (56%)
65	88 (50%)	86 (49%)
75	80 (45%)	78 (44%)
85	77 (44%)	75 (42%)

Across all 1,134 studies, recruiting or not: 56% stop at 75 or younger and 54% at 65; 65% take children; 2% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Anemia, Sickle Cell studies take

Of 92 phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	36 mo18–65 · 58 studies	24 mo9–41 · 28 studies	—
Phase 1/2	82 mo44–222 · 37 studies	—	—
Phase 2	46 mo24–73 · 92 studies	28 mo16–41 · 34 studies	54 mo42–117 · 58 studies
Phase 3	48 mo36–61 · 35 studies	—	—
Phase 4	24 mo13–41 · 20 studies	—	—
Interventional, no phase	28 mo15–49 · 173 studies	—	28 mo17–54 · 165 studies
Observational	49 mo24–109 · 139 studies	—	48 mo23–109 · 130 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Show 2 more

Evolution of Sickle Cell MaculopathyOct 16, 2026NCT07877753
Self-administered Acupressure in Patients With Sickle Cell DiseaseOct 15, 2026NCT07875777

Studies

Recruiting first, then most recently updated. Showing 50 of 1,134. Browse all 1,134 → or search them.